Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

[Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas]

[Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas] Abstract Text:

    yu-jing zhangYu-jing Zhang,zhong-min renZhong-min Ren,qiu-liang wuQiu-liang Wu,zhen-yu heZhen-yu He,yan huangYan Huang,yun-fei xiaYun-fei Xia,tong-yu linTong-yu Lin,nian-ji cuiNian-ji Cui,

    OBJECTIVE: To retrospectively analyze the treatment outcomes and prognostic factors of nasal and nasopharyngeal peripheral T cell lymphomas (PTCL) patients. METHODS: One hundred and twelve patients with pathologically confirmed nasal and nasopharyngeal PTCL were included, among which 39 were CD56(+) NK/T cell lymphomas. The median pre-treatment disease course was 4 months. 84 were males and 28 females median age was 46 years. The tumors mainly involved nasal cavity (88 cases) and/or nasopharynx (50 cases) and adjacent structures, and 83 cases with extra-cavity diseases. 91.1% of the patients had Ann Arbor I(E)/II(E) diseases. The International Prognostic Indices (IPI) were less than 2 scores in 78.8% of the patients. Seventy two patients received combined chemo-radiotherapy, 32 chemotherapy only, 3 radiotherapy only and 5 no any treatment. RESULTS: Median follow-up duration was 42 months. Chemotherapy achieved a complete remission (CR) rate of 34.4% for initial treatment, and of 65.1% after primary treatment. The local tumor controlled rate was 50.5%, and the median time to tumor progression (TTP) was 11 months. There were evidences of systemic relapse in more than 30% of the patients. The extra-cavity tumors usually had a shorter TTP (r(s) = -0.191, P = 0.024). The progress-free survival and overall survival rates were 38.8% and 52.4% at 3 years, and 34.9% and 44.8% at 5 years respectively. Univariate analysis showed that favorable prognostic factors for survival were pre-treatment course > 3 months, earlier clinical stage, non NK/T lymphoma, no skin involvement, lower IPI, CR after initial chemotherapy, radiotherapy, CR after primary treatment and local tumor controlled. Multivariate analysis showed that, pre-treatment course > 3 months (P = 0.011), non NK/T lymphoma (P = 0.007), CR after initial chemotherapy (P = 0.008) and radiotherapy (P = 0.000) were favorable prognostic factors for survival. CONCLUSIONS: Although most nasal and nasopharyngeal peripheral T-cell lymphomas were diagnosed at early stage diseases, some of them were highly aggressive with poor prognosis, particularly CD56(+) NK/T cell lymphomas. Combination chemo/radiotherapy, though remained principal treatments, more effective therapeutic modalities are expected.

    [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas] Publishing Authors By Initials

    yj zhangYJ Zhang,zm renZM Ren,ql wuQL Wu,zy heZY He,y huangY Huang,yf xiaYF Xia,ty linTY Lin,nj cuiNJ Cui,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas] Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zaz

    VOLUME: 27

    Page Numbers: 217-21

    Journal Abbreviation:

    ISSN: 0253-2727

    DAY: 31

    MONTH: Apr

    YEAR: 2006

    [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas] Information

    Number of References:

    LANGUAGE: chi

    NlmUniqueID: 8212398

    [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas] Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas] Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for [Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas]

    AFFILIATION: Department of Radiation Oncology, State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China.

    Country: China

    China Research PublicationChina Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Zhonghua Xue Ye Xue Za Zhi

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Treatment outcome and prognosis of 112 patients with nasal and nasopharyngeal peripheral T cell lymphomas Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News